GeneDx faces securities fraud probe after missing revenue targets and stock plunges 49%.

Pomerantz LLP is investigating GeneDx Holdings Corp. for potential securities fraud after the company reported lower-than-expected Q1 2026 revenue and cut its full-year guidance. Despite 34% growth in test volumes, revenue growth lagged at 27%, with total revenue falling $12 million short of expectations due to lower reimbursement rates and weak non-core business performance. Following the announcement, GeneDx's stock dropped nearly 50%, prompting the investigation into possible unlawful practices by the company and its executives.